Exact Mass: 502.10869979999995
Exact Mass Matches: 502.10869979999995
Found 27 metabolites which its exact mass value is equals to given mass value 502.10869979999995,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
6'-O-Malonyldaidzin
Present in soy foods; potential nutriceutical. 6-Malonyldaidzin is found in many foods, some of which are soy milk, soy sauce, soy bean, and soy yogurt. 6-O-Malonyldaidzin is found in miso. 6-O-Malonyldaidzin is present in soy foods; potential nutriceutical.
Apigenin 7-(2-acetyl-6-methylglucuronide)
9,10-Anthracenedione, 8-[[6-O-(2-carboxyacetyl)-beta-D-glucopyranosyl]oxy]-1-hydroxy-3-methyl-
7-O-[6-O-(3,4-dihydroxycinnamoyl)-beta-D-glucopyranosyl]-8-hydroxycoumarin
13-hydroxy-7-(6-O-sulfate-beta-D-glucopyranosyl)desoxyhemigossypol
C21H26O12S (502.11449160000006)
3,5-Bis(3,5-dimethoxybenzyloxy)benzyl Bromide
C25H27BrO6 (502.09909020000003)
Fisogatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor D000970 - Antineoplastic Agents
Capmatinib Hydrochloride
C23H21Cl2FN6O2 (502.10869979999995)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
Bis[5-chloro-1H-indol-2-YL-carbonyl-aminoethyl]-ethylene glycol
Malonyldaidzin
A glycosyloxyisoflavone that is daidzein substituted by a 6-O-(carboxyacetyl)-beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.
7-Methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3,4,5-trihydroxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one
[2-[(4-Fluorophenyl)methylamino]-2-oxoethyl] 1-[2-(trifluoromethyl)phenyl]sulfonylpiperidine-4-carboxylate
C22H22F4N2O5S (502.11854900000003)
N-[[4-[(2,6-difluorophenyl)sulfonylamino]cyclohexyl]methyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide
7-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3,4,5-trihydroxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one
6-[1-(3,4-Dihydroxyphenyl)-3-(4-methoxy-1-benzofuran-5-yl)-1,3-dioxopropan-2-yl]-3,4,5-trihydroxyoxane-2-carboxylic acid
1-[1-(2-chlorophenyl)-3-(pyridin-3-yl)-4,5-dihydro-1H-[1,3]thiazolo[4,5-g]indazol-7-yl]-3-(1H-imidazol-2-ylmethyl)urea
C24H19ClN8OS (502.10909940000005)
GSK2647544
GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages[1].